Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
2023 · The Lancet · 214 citations
https://doi.org/10.1016/s0140-6736(22)02038-4
H
Hiroshi Ishii
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
303
Papers
7.4K
Citations
48
h-index
120
i10-index
Hiroshi Ishii is an academic researcher from Kanazawa University. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cholangiocarcinoma and Gallbladder Cancer Studies & Hepatocellular Carcinoma Treatment and Prognosis. The author has an h-index of 48, co-authored 258 publications.
ORCID: 0000-0002-3295-4867Papers by this author
worksSorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
2016 · Annals of Oncology · 165 citations
https://doi.org/10.1093/annonc/mdw323
Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
2017 · Journal of Gastroenterology · 88 citations
https://doi.org/10.1007/s00535-017-1374-6
Association between variations in the fat mass and obesity-associated gene and pancreatic cancer risk: a case–control study in Japan
2013 · BMC Cancer · 58 citations
https://doi.org/10.1186/1471-2407-13-337
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
2015 · British Journal of Cancer · 58 citations
https://doi.org/10.1038/bjc.2015.103
Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer
2020 · Nature Communications · 58 citations
https://doi.org/10.1038/s41467-020-16711-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat